The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors

The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors

Cancer immunotherapy with antibodies targeting immune checkpoints such as the PD-1/PD-L1 pathway have emerged as breakthrough treatment for multiple solid tumors with high response rates and durable remissions. Despite the benefit for patients and encouraging safety profile, severe inflammatory reac...

Full description

Bibliographic Details
Main Authors: Heinz Läubli, Viktor H. Koelzer, Matthias S. Matter, Petra Herzig, Béatrice Dolder Schlienger, Mark Nikolaj Wiese, Didier Lardinois, Kirsten D. Mertz, Alfred Zippelius
Format: Article
Language:English
Published: Taylor & Francis Group 2018-02-01
Series:OncoImmunology
Subjects:
cancer immunotherapy
immune-related adverse event
pd-1
tumor-infiltrating t cells
t cell receptor
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1386362

Internet

http://dx.doi.org/10.1080/2162402X.2017.1386362

Similar Items